➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Mallinckrodt
Moodys
Merck
McKinsey

Last Updated: June 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,759,350


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,759,350
Title:Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
Inventor(s): Kikuchi; Tetsuro (Tokushima, JP), Iwamoto; Taro (Princeton, NJ), Hirose; Tsuyoshi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:10/540,577
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,759,350
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 8,759,350

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka ABILIFY aripiprazole SOLUTION;ORAL 021713-001 Dec 10, 2004 DISCN Yes No   Start Trial   Start Trial ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-002 Jun 7, 2006 DISCN Yes No   Start Trial   Start Trial ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-003 Jun 7, 2006 DISCN Yes No   Start Trial   Start Trial ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,759,350

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2002-379003Dec 27, 2002
PCT Information
PCT FiledDecember 25, 2003PCT Application Number:PCT/JP03/16724
PCT Publication Date:July 22, 2004PCT Publication Number: WO2004/060374

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
AstraZeneca
Moodys
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.